Quantum Cyber (formerly Mainz Biomed) Announces Major Leadership and Strategic Changes
Key Highlights and Investor-Relevant Developments
- Appointment of Robert Liscouski as Chairman of the Board
- Company Name Change to Quantum Cyber
- New Nasdaq Ticker Symbol: QUCY (effective March 12, 2026)
- Strategic Focus Shift: Pancreatic Cancer Screening & Asset Sales
- Leadership with Deep Security, AI, and Quantum Computing Expertise
Detailed Overview
Mainz Biomed N.V., a molecular genetics diagnostics company specializing in early cancer detection, has announced a series of transformative changes that are likely to have a significant impact on its future direction and shareholder value.
Leadership Change: Robert Liscouski Appointed Chairman
The company has appointed Robert P. Liscouski as Chairman of the Board of Directors. Mr. Liscouski brings over 35 years of experience spanning public and private sectors, with a strong emphasis on homeland security, cybersecurity, and technological innovation. He is widely recognized for his contributions on platforms such as CNBC, CNN, BBC, and Fox News, and has testified before Congress on security issues.
Mr. Liscouski holds a Master of Public Administration from Harvard University’s John F. Kennedy School of Government. His government service includes a pivotal role as the first Assistant Secretary for Infrastructure Protection at the US Department of Homeland Security during its founding post-9/11. He was instrumental in integrating various agencies (FBI, DoD, GSA, Department of Energy, Commerce) and creating the National Cyber Security Division, which led to the formation of today’s Critical Infrastructure and Security Agency (CISA).
Company Rebranding and Ticker Change
In a move that signals a new strategic direction, Mainz Biomed will change its name to Quantum Cyber, with its Nasdaq ticker symbol shifting from MYNZ to QUCY starting March 12, 2026. This change will be formally ratified at an extraordinary general meeting scheduled for April 2026. The company will begin trading under its new identity and symbol in advance, marking a significant milestone in its transformation.
Strategic Refocus: Cancer Screening and Asset Management
The company has reaffirmed its commitment to the development of its pancreatic cancer screening business in the U.S. It is actively exploring opportunities to sell its colorectal cancer screening assets and is winding down its German subsidiary. This strategic pivot is intended to streamline operations and focus on high-growth, high-impact areas.
Technological and Security Expertise
Mr. Liscouski’s appointment brings high-caliber technology and security expertise. He was most recently co-founder, CEO, and Chairman of Quantum Computing Inc., a leader in photonics-based quantum machines. His innovations also extend to artificial intelligence and high-performance computing, notably through Fog Data Sciences, which provides geo-location intelligence solutions for law enforcement and the US Security and Intelligence Community. Previously, he served as Director of Information Assurance at The Coca-Cola Company, designing and implementing information security strategies.
Management Comments
David Lazar, the outgoing Chairman, described Mr. Liscouski as a perfect fit for the company’s evolving high-tech and cybersecurity ambitions, highlighting his role as a technology leader and his successful track record at Quantum Computing Inc., the first pure-play public quantum computing company focusing on nano-photonic hardware.
Potential Share Price Sensitivity
- Leadership Change: The appointment of a prominent technology and security leader may boost investor confidence, especially given Mr. Liscouski’s public profile and industry connections.
- Rebranding and Ticker Change: The shift to Quantum Cyber and the new ticker could attract new investors, aligning the company with hot trends in cybersecurity and quantum computing.
- Strategic Refocus: The sale of non-core assets and concentration on high-value cancer screening technologies could improve profitability and position the company for growth.
- AI and Quantum Technology: With leadership experienced in quantum and AI, the company could pursue innovative product development and partnerships, potentially accelerating revenue opportunities.
Forward-Looking Statements
The company cautions investors that these statements are forward-looking and subject to risks and uncertainties. Factors such as failure to meet development targets, regulatory changes, inability to execute new initiatives, and other risks disclosed in SEC filings could materially impact performance.
Investor Contact
For further investor inquiries, contact Andrew J. Barwicki at 516-662-9461 or [email protected].
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should review the company’s filings with the SEC for detailed risk disclosures and consult their financial adviser before making investment decisions.
